H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10

Futu NewsDec 21, 2024 02:31 · Ratings

Aquestive Therapeutics Gains Buy Rating Amid Orphan Drug Exclusivity and Promising Product Pipeline

TipRanksDec 21, 2024 02:25 · Ratings

Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)

TipRanksDec 21, 2024 01:49 · Ratings

Aquestive Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow JonesDec 20, 2024 20:52 · Ratings

Sector Update: Health Care Stocks Lower Thursday Afternoon

MT NewswiresDec 20, 2024 02:49

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity For Libervant Buccal Film In Pediatric Patients With Seizure Clusters Ages 2-5

BenzingaDec 19, 2024 21:09